Log in to your Inderes Free account to see all free content on this page.

Senzime

5.35 SEK

-3.95 %

Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-3.95 %

+6.79 %

-16.54 %

+4.49 %

-2.73 %

-5.14 %

-51.65 %

-75.34 %

-9.85 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Market cap

841.1M SEK

Turnover

756.16K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.2.

2026

Annual report '25

22.4.

2026

Interim report Q1'26

19.5.

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Press release12/17/2025, 7:45 AM

Senzime’s Next-generation TetraGraph system receives regulatory approval in Japan

Press release12/10/2025, 12:30 PM

Senzime unveils the next set of innovations in neuromuscular monitoring with the launch of EMGINE Sirius

Press release12/9/2025, 8:00 AM

Senzime secures major TetraGraph order from leading UK NHS hospital system

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release11/19/2025, 7:09 AM

BioStock: Video from Senzime's presentation at BioStock Life Science Summit 2025

Press release11/11/2025, 12:00 PM

Senzime to Present at Redeye and BioStock Investor Conferences

Press release11/3/2025, 1:45 PM

Nomination Committee for Senzime Annual General Meeting 2026

Press release10/30/2025, 1:49 PM

Redeye: Senzime (Q3 Review) - In the right direction

Regulatory press release10/29/2025, 7:30 AM

SENZIME Q3 2025: STRONG GROWTH AND CLEAR STEPS TOWARDS PROFITABILITY

Press release10/23/2025, 9:00 AM

Invitation to presentations of Senzime’s third quarter 2025 report

Press release10/8/2025, 11:00 AM

Senzime launches EMGINE, the next-generation software suite advancing neuromuscular monitoring

Press release10/3/2025, 12:30 PM

Senzime welcomes new European pediatric guidelines recommending EMG-based neuromuscular monitoring

Press release9/17/2025, 11:15 AM

Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center

Press release9/12/2025, 8:00 AM

Senzime to Present at Pareto Securities’ 16th Annual Healthcare Conference

Press release9/12/2025, 7:00 AM

Senzime launches integration with Mindray patient monitors

Press release9/9/2025, 9:00 AM

Senzime welcomes new Japanese guidelines on neuromuscular monitoring

Press release9/8/2025, 11:15 AM

Senzime to Present at the European Growth Virtual Investor Conference on September 11

Press release9/4/2025, 2:30 PM

Extensive Clinical and Competitive Evaluation Leads Major California University Hospital System to Standardize on Senzime’s TetraGraph System

Press release9/4/2025, 9:06 AM

Redeye: Redeye Initiates Coverage of Senzime

Press release8/5/2025, 9:00 AM

Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System

Regulatory press release7/31/2025, 1:00 PM

New number of shares and votes in Senzime AB (publ)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.